Everest Medicines Limited (HKG:1952)
33.66
+9.86 (41.43%)
Aug 20, 2026, 4:09 PM HKT
Everest Medicines Revenue
Everest Medicines had revenue of 1.26B CNY in the half year ending December 31, 2025, with 977.06% growth. This brings the company's revenue in the last twelve months to 2.41B, up 182.91% year-over-year. In the year 2025, Everest Medicines had annual revenue of 1.71B with 141.51% growth.
Revenue (ttm)
2.41B CNY
Revenue Growth
+182.91%
P/S Ratio
4.25
Revenue / Employee
2.97M CNY
Employees
812
Market Cap
11.83B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.71B | 1.00B | 141.51% |
| Dec 31, 2024 | 706.68M | 580.75M | 461.16% |
| Dec 31, 2023 | 125.93M | 113.14M | 884.46% |
| Dec 31, 2022 | 12.79M | 12.74M | 23,588.89% |
| Dec 31, 2021 | 54.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Haohai Biological Technology | 2.73B |
| Lepu Biopharma | 1.04B |
| Abbisko Cayman | 681.17M |
| Alphamab Oncology | 630.11M |
| CStone Pharmaceuticals | 299.99M |
| Suzhou Ribo Life Science | 165.26M |
| CARsgen Therapeutics Holdings | 157.72M |
| Ascletis Pharma | 2.26M |
Everest Medicines News
- 1 day ago - Everest Medicines Earnings Call Transcript: H1 2026 - Transcripts
- 1 day ago - Everest Medicines Earnings release: H1 2026 - Filings
- 2 months ago - LENZ Therapeutics Secures $85 Million Potential from Everest Medicines Deal - GuruFocus
- 2 months ago - Everest Medicines Acquires Rights To Develop And Commercialize VIZZ In Greater China - Nasdaq
- 2 months ago - LENZ Announces Everest Medicines' Acquisition of VIZZ Rights in Greater China - GuruFocus
- 2 months ago - Travere Therapeutics Partners with Everest Medicines for $1.14 Billion Kidney Drug Deal - GuruFocus
- 4 months ago - Everest Medicines Slides: Acquisition presentation - Filings
- 4 months ago - China biotech flow picks up as Everest seals US$250 million deal - South China Morning Post